Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 14, 2016

Study Completion Date

November 14, 2016

Conditions

Malignant Pleural Mesothelioma

Interventions

BIOLOGICAL

HSV1716 Intra-pleural delivery

Trial Locations (2)

Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

Queen Elizabeth Univeristy Hospital, NHS Greater Glasgow & Clyde Health Board, Glasgow

All Listed Sponsors

lead

Virttu Biologics Limited

INDUSTRY

NCT01721018 - Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. | Biotech Hunter | Biotech Hunter